Cipher Pharmaceuticals (CPH)

CPH Dermatology / Acne

BiotechSign Signal Grade

Signal Grade

1.2/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying

Publications

100

Clinical Activity

Pipeline Overview

Therapeutic Focus: Dermatology / Acnesrc

Clinical Trial Activity

Clinical Trials
(ClinicalTrials.gov aggregate)

PubMed Publications

Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov

Recent Publications

CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer. — J Immunother Cancer 2026 Sep 18 Muneer A PMID 42759982
Characteristics of Authorized Clinical Trials in Peru, 2017-2025: A National Registry-Based Study. — Ther Innov Regul Sci 2026 Aug 31 Mendoza-Aucaruri L PMID 42671713
Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies. — Lancet 2026 Aug 15 Passeron T PMID 42594914
Molecular Editing Reveals a Bilobalide Chemotype that Attenuates Prolyl Endopeptidase (PREP)-Linked Neuroinflammation. — Adv Sci (Weinh) 2026 Aug 11 Sillapachaiyaporn C PMID 42579630
A quasi-experimental effectiveness evaluation of a nurse-led Hospital Violence Intervention Programme in the United Kingdom using linked routine health and administrative data. — EClinicalMedicine 2026 Apr Moore SC PMID 41953820

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Cipher Pharmaceuticals.

Full CPH Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.